Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apraclonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 9/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 8/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 8/20 | 0.97 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.97 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.97 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 5/20 | 0.72 |
| ▸ | HTR1D | P28221 | 4/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.69 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.69 |
| ▸ | HTR1B | P28222 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | HTR7 | P34969 | 1/20 | 0.67 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apraclonidine SCHEMBL34128 | 0.98 | ADRA2A (1.00) | BLMADRA2AADRA2BADRA2CADRA1A | |
| Apraclonidine SCHEMBL1649431 | 0.97 | ADRA2A (0.97) | BLMADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL11180812 | 0.85 | ADRA2A (0.76) | BLMADRA2AADRA2BADRA2CADRA1A | |
| Pi-Clonidine SCHEMBL5274141 | 0.84 | LMNA (1.00) | BLMADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL24658874 | 0.82 | ADRA2A (0.71) | BLMADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL10414088 | 0.82 | ADRA2A (0.71) | BLMADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL11761437 | 0.82 | ADRA2C (0.71) | BLMADRA2AADRA2BADRA2CADRA1A | |
| Pi-Clonidine SCHEMBL563884 | 0.82 | ADRA2A (1.00) | BLMADRA2AADRA2BADRA2CADRA1A | |
| Bromide SCHEMBL11608848 | 0.81 | ADRA2A (0.69) | BLMADRA2AADRA2BADRA2CADRA1A | |
| Hydrochloric Acid SCHEMBL10973842 | 0.81 | HTR1D (0.69) | BLMADRA2AADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11206977-B2 | Vision test for determining retinal disease progression | THE TRUSTEES OF THE UNIVERSITY OF PENNYSLVANIA (US) | 2021-12-28 | — | — | US | claimed |
| US-20170354324-A1 | VISION TEST FOR DETERMINING RETINAL DISEASE PROGRESSION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-12-14 | — | — | US | claimed |
| US-9371387-B2 | Composition for prevention or treatment of ischemic cardiac disease, comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-06-21 | — | — | US | claimed |
| US-20140234343-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF ISCHEMIC CARDIAC DISEASE, COMPRISING INHIBITOR AGAINST AGE-ALBUMIN SYNTHESIS OR RELEASE OF MONONUCLEAR PHAGOCYTE SYSTEM CELLS AS ACTIVE INGREDIENT | NSAGE CORP. (KR) | 2014-08-21 | — | — | US | claimed |
| US-20130142733-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | VANDERBILT UNIVERSITY (US) | 2013-06-06 | — | — | US | claimed |
| CN-102741396-A | Small molecules to support growth of pluripotent cells and methods thereof | VIACYTE INC | 2012-10-17 | — | — | CN | claimed |
| US-20110274620-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | NATIONAL SCIENCE FOUNDATION | 2011-11-10 | — | — | US | claimed |
| WO-2010129294-A2 | SMALL MOLECULES SUPPORTING PLURIPOTENT CELL GROWTH AND METHODS THEREOF | SCHULZ THOMAS C (US) | 2010-11-11 | — | — | WO | claimed |
| US-12102628-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation | 2024-10-01 | — | — | US | disclosed |
| US-20240307355-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING APRACLONIDINE FOR OCULAR REDNESS RELIEF | ALCON RESEARCH, LLC | 2024-09-19 | — | — | US | disclosed |
| EP-3654964-B1 | COMPOSITION COMPRISING ATROPINE AND A MIOTIC AGENT AND ITS USE IN THE TREATMENT OF MYOPIA | SEINDA PHARMACEUTICAL GUANGZHOU CORP (CN) | 2024-04-24 | — | — | EP | disclosed |
| US-20230062844-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2023-03-02 | — | — | US | disclosed |
| US-11285141-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation (CN) | 2022-03-29 | — | — | US | disclosed |
| US-11254786-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | VANDERBILT UNIVERSITY (US) | 2022-02-22 | — | — | US | disclosed |
| WO-1997046239-A1 | TREATMENT OF LIPID AND GLUCOSE METABOLISM DISORDERS WITH DOPAMINE AND SEROTONIN AGONISTS | ERGO RESEARCH CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0590786-B1 | Use of certain anionic surfactants to enhance antimicrobial effectiveness of opthalmic compositions | ALCON LAB INC (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5684156-A | Process for preparation of clonidine derivatives | ALCON RESEARCH, LTD. | 1997-11-04 | — | — | US | disclosed |
| EP-0711147-A1 | SUSPENSIONS FOR DELIVERY OF MEDICAMENT | INSITE VISION INCORPORATED (US) | 1996-05-15 | — | — | EP | disclosed |
| US-5516808-A | ANTIBIOTIC GEL | SAWAYA ASSAD S (US) | 1996-05-14 | — | — | US | disclosed |
| WO-1995003784-A1 | SUSPENSIONS FOR DELIVERY OF MEDICAMENT | INSITE VISION INCORPORATED (US) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254786-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | DSTN, PARN, CTSA | ADRA2A 1802/4885ADRA2B 2687/4885ADRA2C 2355/4885 |
| US-12102628-B2 | Composition and methods for the treatment of myopia | CHRM3, CHRM2, MYOC | ADRA2A 56/4885ADRA2B 50/4885ADRA2C 79/4885 |
| US-20110274620-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | DSTN, PARN, CTSA | ADRA2A 1802/4885ADRA2B 2687/4885ADRA2C 2355/4885 |
| US-11285141-B2 | Composition and methods for the treatment of myopia | CHRM3, CHRM2, MYOC | ADRA2A 56/4885ADRA2B 50/4885ADRA2C 79/4885 |
| US-20230062844-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA | CHRM3, CHRM2, MYOC | ADRA2A 56/4885ADRA2B 50/4885ADRA2C 79/4885 |
| US-20130142733-A1 | MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES | DSTN, PARN, CTSA | ADRA2A 1802/4885ADRA2B 2687/4885ADRA2C 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.